Sarepta Therapeutics Restructuring

Order byBest matchMost fresh

Sarepta, Restructuring Plan

Sarepta Therapeutics Stock Soars on Beleaguered Drugmaker's Restructuring Plan

Shares of struggling drug developer Sarepta Therapeutics ( SRPT) skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

· 3d · on MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

· 3d · on MSN

Sarepta Therapeutics to Restructure, Lay Off 500 Workers

· 1d

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics (SRPT.O) to voluntarily stop all shipments of its gene therapy, Elevidys, a source familiar with the matter told Reut...

· 1d

FDA to ask Sarepta to stop shipping Duchenne gene therapy

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Business Wire3d

Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan

1don MSN

Gene-therapy company to eliminate 21 Durham employees as part of major restructuring

Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an effort to cut annual operating costs by hundreds of millions of dollars.

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its outlook. Click for my SRPT stock update.

Hoodline23h

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Schaeffer's Investment Research2d

Biotech Stock Soars on Restructuring Plan, Layoffs

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 employees -- more than a third of its workforce -- after two deaths following treatment with its gene therapy for fatal muscle disorder,